| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Acquisitions, net of cash acquired | 3,000 | 0 | - | 5,000 |
| Net cash used in investing activities | -849,400 | -446,500 | 647,500 | -2,818,700 |
| Proceeds from issuance of common stock | 132,400 | 92,100 | 60,600 | 1,374,400 |
| Payments in connection with common stock tendered for employee tax obligations | 12,900 | 9,900 | 4,300 | 775,700 |
| Repurchases of common stock | 2,766,900 | 2,102,900 | 1,041,400 | 1,630,300 |
| Dividends paid | 277,600 | 186,400 | 93,800 | - |
| Other | -10,300 | -10,300 | -10,300 | -33,400 |
| Net cash used in financing activities | -2,935,300 | -2,217,400 | -1,089,200 | -1,065,000 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 600 | 1,000 | 600 | 0 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 24,100 | -473,400 | 604,000 | -726,000 |
| Cash and cash equivalents at beginning of period | 2,489,000 | 2,489,000 | 2,489,000 | 2,737,800 |
| Cash and cash equivalents at end of period | 2,513,100 | 2,015,600 | 3,093,000 | 2,011,800 |
REGENERON PHARMACEUTICALS, INC. (REGN)
REGENERON PHARMACEUTICALS, INC. (REGN)